News > Two AstraZeneca drugs get EU backing for treatment of some breast cancers

Two AstraZeneca drugs get EU backing for treatment of some breast cancers

27/06/2022 01:25 PM | Click to read full article

AstraZeneca said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio.

Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer.